NCT03527212: An overdue trial by Senju Pharmaceutical Co., Ltd.
This trial is overdue. It was due to report 6 years, 7 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT03527212 |
|---|---|
| Title | A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of SJP-0035 0.001% for the Treatment of Patients With Dry Eye Disease (DELTA-1 Study) |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 20, 2018 |
| Completion date | March 15, 2019 |
| Required reporting date | March 14, 2020, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | 2411 |